EYPT Latest Headlines

RBC Capital Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT)

at www.tipranks.com (Thu, 6-Aug 7:09 AM)

Analyst Reiterates Buy on EYPT Ahead of Pivotal LUGANO Phase III Data and Favorable Risk-Reward Profile

at www.tipranks.com (Thu, 6-Aug 5:57 AM)

Analysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT) and EyePoint Pharmaceuticals (EYPT)

at www.tipranks.com (Wed, 5-Aug 3:30 PM)

Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), EyePoint Pharmaceuticals (EYPT) and Green Thumb Industries (OtherGTBIF)

at www.tipranks.com (Wed, 5-Aug 9:50 AM)

EyePoint Pharmaceuticals GAAP EPS of -$1.09 misses by $0.13, revenue of $0.5M beats by $0.13M

at seekingalpha.com (Wed, 5-Aug 7:30 AM)

EyePoint Wraps Up Phase 3 DURAVYU Enrollment Early, Signaling Strong Momentum for Diabetic Macular Edema Progress

Market Chameleon (Thu, 30-Jul 9:41 AM)